Boardroom Alpha
Boardroom Alpha
LBRX · Additional Proxy Materials (DEFA14A) · Filed April 23, 2026

Lb Pharmaceuticals Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 23, 2026
Ticker
LBRX
Accession
0001193125-26-173708
Boardroom Alpha · Filing insights

LB Pharmaceuticals Inc.'s DEFA14A backs a three-director slate and ratification of BDO as auditor.

About Lb Pharmaceuticals Inc
Market cap
$1.5B
Board grade
B-
Sector
Healthcare
CEO
Heather D Turner
Last annual meeting: Jun 3, 2026 · View full Lb Pharmaceuticals Inc profile →
DEFA14A
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

 

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

LB Pharmaceuticals Inc

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 
 


LOGO

Your Vote Counts! LB PHARMACEUTICALS INC 2026 Annual Meeting of Stockholders Vote by June 2, 2026 11:59 PM ET LB PHARMACEUTICALS INC ONE PENNSYLVANIA PLAZA, SUITE 1025 NEW YORK, NY 10119 V95415-P50676 You invested in LB PHARMACEUTICALS INC and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 3, 2026 at 9:30 a.m. Eastern Time, at www.virtualshareholdermeeting.com/LBRX2026 and any adjournment or postponement thereof. Get informed before you vote View the Notice, Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 20, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Vote Virtually at the Meeting* Point your camera here and June 3, 2026 9:30 a.m. Eastern Time vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/LBRX2026 *Please check the meeting materials for any special requirements for meeting attendance.


LOGO

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting as described in the more complete proxy materials that are available to you on the Internet. Please follow the instructions on the reverse side to vote these important matters. Before voting, we encourage you to access and review all of the important information contained in the proxy materials. Board Voting Items Recommends 1. To elect three nominees for Class I directors, each to hold office until the 2029 Annual Meeting of Stockholders. Nominees: For 01) Robert A. Lenz M.D., Ph.D. 02) Rebecca Luse 03) Ran Nussbaum 2. To ratify the appointment by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company’s For independent registered public accounting firm for the fiscal year ending December 31, 2026. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournments or postponements thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V95416-P50676

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Lb Pharmaceuticals Inc (LBRX)

Reference

Frequently asked questions

When did Lb Pharmaceuticals Inc file this DEFA14A?
Lb Pharmaceuticals Inc (LBRX) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 23, 2026. The accession number assigned by EDGAR is 0001193125-26-173708.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
LB Pharmaceuticals Inc.'s DEFA14A backs a three-director slate and ratification of BDO as auditor. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Lb Pharmaceuticals Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Lb Pharmaceuticals Inc has filed under CIK 1691082, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer